Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast
- 24 June 2017
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 165 (3) , 757-763
Abstract
Invasive lobular carcinoma (ILC) of the breast has unique clinicopathologic characteristics, compared to invasive ductal carcinoma. The role of the 21-gene Recurrence Score (RS) has not been clearly defined for ILC. We sought to determine the prognostic value of RS and the impact of adjuvant chemotherapy on long-term survival in patients with ILC.Keywords
This publication has 21 references indexed in Scilit:
- Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast CancerAnnals of Surgical Oncology, 2015
- Multigene prognostic tests in breast cancer: past, present, futureBreast Cancer Research, 2015
- Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancerAnnals of Oncology, 2012
- Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancersCancer, 2010
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20Journal of Clinical Oncology, 2010
- Lobular and ductal carcinomas of the breast have distinct genomic and expression profilesOncogene, 2008
- Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomesEuropean Journal of Cancer, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Recent developments: Breast cancerBMJ, 2002